Why the study?
Glycated hemoglobin reduction extent and glycemic control duration affect cardiovascular outcomes, motivating investigation into how metformin plus DPP4 inhibitors versus sulfonylureas impacts long-term clinical outcomes in AMI patients with type 2 DM.
Does metformin combined with DPP4 inhibitors reduce major adverse cardiac events and recurrent myocardial infarction compared to metformin combined with sulfonylureas in patients with acute myocardial infarction and type 2 diabetes mellitus?
Does metformin combined with DPP4 inhibitors reduce major adverse cardiac events and recurrent myocardial infarction compared to metformin combined with sulfonylureas in patients with acute myocardial infarction and type 2 diabetes mellitus?
In patients with acute myocardial infarction and type 2 diabetes undergoing PCI with drug-eluting stents, combining metformin with DPP4 inhibitors rather than sulfonylureas did not significantly reduce 3-year MACE, but was associated with a significantly lower risk of recurrent myocardial infarction.
Answers are grounded in this paper and cite their sources.
MET plus DPP4 inhibitors was associated with fewer recurrent MIs than plus sulfonylureas in AMI with diabetes; leaves open need for randomized confirmation.
Background: Recent trials have shown that both the extent of glycated hemoglobin reduction and the duration of enhanced glycemic control are major factors that may affect cardiovascular outcome results. We aimed to investigate the impact of metformin (MET) combined with dipeptidyl peptidase-4 (DPP4) inhibitors or sulfonylureas (SU) on long-term clinical outcomes in patients with acute myocardial infarction (AMI) and type 2 diabetes mellitus (DM). Methods: This study was a prospective cohort trial. From November 2011 to December 2015, a total of 13,104 AMI patients were consecutively enrolled from the Korea AMI registry-National Institutes of Health. The patients were divided into the MET + DPP4 inhibitors group and the MET + SU group. The primary endpoint, major adverse cardiac events (MACE), was defined as the composite of all-cause death, recurrent myocardial infarction (MI), and any repeat revascularization up to 3-year follow-up. To adjust baseline potential confounders, an inverse probability weighting (IPTW) analysis was performed. Results: Baseline well-matched two groups were generated (the MET + DPP4 inhibitors group, n=468 and the MET + SU group, n=468). During 3-year clinical follow-up, the cumulative incidence of MACE between the two groups was not significantly different after adjustment (16.8% for MET + DPP4 inhibitors group vs. 19.4% for MET + SU group, P=0.302). However, the MET + DPP4 inhibitors group was associated with reduced risk of MI [1.3% vs. 4.9%; hazard ratio (HR): 0.228, 95% confidence interval (CI): 0.090–0.580, P=0.001] than the MET + SU group. Conclusions: In patients with AMI and type 2 DM, the use of MET combined with DPP4 inhibitors was associated with reduced incidence of recurrent MI than MET combined with SU during 3-year follow-up.
No takes yet. Share an insight, caveat, or question.
Her et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: